Nonalcoholicsteatohepatitis (NASH) Pipeline Analysis: Revenue Growth, Key Players, Qualitative Analysis, Quantitative Analysis, Forecast 2020-2030

Japan, Japan, Tue, 07 Dec 2021 01:56:57 / Comserve Inc. / -- This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers.

"Non-alcoholic steatohepataitis (NASH) Pipeline Analysis" gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report also covers some of the hot targets in research for NASH treatments and NASH related biomarkers.

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Non-alcoholic steatohepataitis (NASH) drugs market. The report also provides strategic insights on some of the molecules that are yet to be launched in the next few years.

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-78180

Some of the key sections covered in the report are given below:
• Epidemiology
o In this section, epidemiology of NASH is reviewed to understand potential significance and impact of the disease.
o Global & US prevalence rates.
• Hot Targets, Mechanisms & Therapies
o In this section, various NASH associated targets, mechanism and upcoming therapies are discussed. Also, covers novel targets in early research for NASH along with disease progression biomarkers associated with NASH (Inflammatory, apoptosis, fibrosis).
• Pipeline Analysis
o Pipeline analysis was carried to get deeper insights on various treatment modalities in discovery, preclinical & development section, pipelines from major companies were identified and Potential targets were reported along with Mechanism of action, Current development status & nature of molecule. Pipeline analysis by developmental stage (Discovery to Clinical development).
o Pipeline analysis by modalities
• Monoclonal Antibodies pipeline analysis
• RNA-therapeutics pipeline analysis
• Recombinant protein pipeline analysis
o Pipeline analysis by leading players & Target analysis
o Drug analysis based on mechanism (Anti-Inflammatory, Anti-fibrotic and Metabolic).

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

For more information, please contact:

Hina Miyazu

Shibuya Data Count
Email: sales@sdki.jp
Tel: + 81 3 45720790

The post Nonalcoholicsteatohepatitis (NASH) Pipeline Analysis: Revenue Growth, Key Players, Qualitative Analysis, Quantitative Analysis, Forecast 2020-2030 appeared first on Comserveonline.

Posted In: